Literature DB >> 23466912

Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β-lactamase-producing enterobacteriaceae on hospital admission.

Steven W Johnson1, Deverick J Anderson, D Byron May, Richard H Drew.   

Abstract

OBJECTIVE: To validate the utility of a previously published scoring model (Italian) to identify patients infected with community-onset extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-EKP) and develop a new model (Duke) based on local epidemiology.
METHODS: This case-control study included patients 18 years of age or more admitted to Duke University Hospital between January 1, 2008, and December 31, 2010, with culture-confirmed infection due to an ESBL-EKP (cases). Uninfected controls were matched to cases (3:1). The Italian model was applied to our patient population for validation. The Duke model was developed through logistic-regression-based prediction scores calculated on variables independently associated with ESBL-EKP isolation. Sensitivities and specificities at various point cutoffs were determined, and determination of the area under the receiver operating characteristic curve (ROC AUC) was performed.
RESULTS: A total of 123 cases and 375 controls were identified. Adjusted odds ratios and 95% confidence intervals for variables previously identified in the Italian model were as follows: hospitalization (3.20 [1.62-6.55]), transfer (4.31 [2.15-8.78]), urinary catheterization (5.92 [3.09-11.60]), β-lactam and/or fluoroquinolone therapy (3.76 [2.06-6.95]), age 70 years or more (1.55 [0.79-3.01]), and Charlson Comorbidity Score of 4 or above (1.06 [0.55-2.01]). Sensitivity and specificity were, respectively, more than or equal to 95% and less than or equal to 47% for scores 3 or below and were less than or equal to 50% and more than or equal to 96% for scores 8 or above. The ROC AUC was 0.88. Variables identified in the Duke model were as follows: hospitalization (2.63 [1.32-5.41]), transfer (5.30 [2.67-10.71]), urinary catheterization (6.89 [3.62-13.38]), β-lactam and/or fluoroquinolone therapy (3.47 [1.91-6.41]), and immunosuppression (2.34 [1.14-4.80]). Sensitivity and specificity were, respectively, more than or equal to 94% and less than or equal to 65% for scores 3 or below and were less than or equal to 58% and more than or equal to 95% for scores 8 or above. The ROC AUC was 0.89.
CONCLUSION: While the previously reported model was an excellent predictor of community-onset ESBL-EKP infection, models utilizing factors based on local epidemiology may be associated with improved performance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23466912      PMCID: PMC3641565          DOI: 10.1086/669858

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  30 in total

Review 1.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions.

Authors:  Lisa M Sullivan; Joseph M Massaro; Ralph B D'Agostino
Journal:  Stat Med       Date:  2004-05-30       Impact factor: 2.373

Review 2.  Clinical prediction rules. A review and suggested modifications of methodological standards.

Authors:  A Laupacis; N Sekar; I G Stiell
Journal:  JAMA       Date:  1997-02-12       Impact factor: 56.272

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 4.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

Authors:  M H Zweig; G Campbell
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

5.  Prevalence and risk factors for multidrug resistant uropathogens in ED patients.

Authors:  S W Wright; K D Wrenn; M Haynes; D W Haas
Journal:  Am J Emerg Med       Date:  2000-03       Impact factor: 2.469

6.  Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital.

Authors:  Eileen M Graffunder; Karen E Preston; Ann M Evans; Richard A Venezia
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

7.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.

Authors:  E Lautenbach; J B Patel; W B Bilker; P H Edelstein; N O Fishman
Journal:  Clin Infect Dis       Date:  2001-03-26       Impact factor: 9.079

8.  Prediction rules to identify patients with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci upon hospital admission.

Authors:  Jon P Furuno; Anthony D Harris; Marc-Oliver Wright; Jessina C McGregor; Richard A Venezia; Jingkun Zhu; Eli N Perencevich
Journal:  Am J Infect Control       Date:  2004-12       Impact factor: 2.918

9.  Preventing the influx of vancomycin-resistant enterococci into health care institutions, by use of a simple validated prediction rule.

Authors:  Evelina Tacconelli; Adolf W Karchmer; Deborah Yokoe; Erika M C D'Agata
Journal:  Clin Infect Dis       Date:  2004-09-08       Impact factor: 9.079

10.  Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia.

Authors:  B-N Kim; J-H Woo; M-N Kim; J Ryu; Y S Kim
Journal:  J Hosp Infect       Date:  2002-10       Impact factor: 3.926

View more
  18 in total

1.  Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Authors:  Zaira Raquel Palacios-Baena; Belén Gutiérrez-Gutiérrez; Marina De Cueto; Pierluigi Viale; Mario Venditti; Alicia Hernández-Torres; Antonio Oliver; Luis Martínez-Martínez; Esther Calbo; Vicente Pintado; Oriol Gasch; Benito Almirante; José Antonio Lepe; Johann Pitout; Murat Akova; Carmen Peña-Miralles; Mitchell J Schwaber; Mario Tumbarello; Evelina Tacconelli; Julia Origüen; Nuria Prim; German Bou; Helen Giamarellou; Joaquín Bermejo; Axel Hamprecht; Federico Pérez; Manuel Almela; Warren Lowman; Po-Ren Hsueh; Carolina Navarro-San Francisco; Julián Torre-Cisneros; Yehuda Carmeli; Robert A Bonomo; David L Paterson; Álvaro Pascual; Jesús Rodríguez-Baño
Journal:  J Antimicrob Chemother       Date:  2017-03-01       Impact factor: 5.790

2.  In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection model.

Authors:  Amira A Bhalodi; Jared L Crandon; Gregory Williams; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

3.  Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1).

Authors:  David A Talan; Sukhjit S Takhar; Anusha Krishnadasan; Fredrick M Abrahamian; William R Mower; Gregory J Moran
Journal:  Emerg Infect Dis       Date:  2016-09       Impact factor: 6.883

4.  Community-Onset Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Invasive Infections in Children in a University Hospital in France.

Authors:  Julie Toubiana; Sandra Timsit; Agnès Ferroni; Marie Grasseau; Xavier Nassif; Olivier Lortholary; Jean-Ralph Zahar; Martin Chalumeau
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

5.  Infections Caused by Extended-Spectrum β-Lactamase Producing Escherichia Coli in Systemic Lupus Erythematosus Patients: Prevalence, Risk Factors, and Predictive Model.

Authors:  Yuetian Yu; Hui Shen; Cheng Zhu; Ruru Guo; Yuan Gao; Liangjing Lu
Journal:  Biomed Res Int       Date:  2018-11-18       Impact factor: 3.411

6.  Using machine learning to guide targeted and locally-tailored empiric antibiotic prescribing in a children's hospital in Cambodia.

Authors:  Mathupanee Oonsivilai; Yin Mo; Nantasit Luangasanatip; Yoel Lubell; Thyl Miliya; Pisey Tan; Lorn Loeuk; Paul Turner; Ben S Cooper
Journal:  Wellcome Open Res       Date:  2018-10-10

7.  Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae--a case-control study in a low prevalence country.

Authors:  Arne Søraas; Arnfinn Sundsfjord; Irene Sandven; Cathrine Brunborg; Pål A Jenum
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

8.  Carriage of extended-spectrum beta-lactamase-producing enterobacteriacae among internal medicine patients in Switzerland.

Authors:  Janet Pasricha; Thibaud Koessler; Stephan Harbarth; Jacques Schrenzel; Véronique Camus; Gilles Cohen; Arnaud Perrier; Didier Pittet; Anne Iten
Journal:  Antimicrob Resist Infect Control       Date:  2013-06-12       Impact factor: 4.887

9.  Independent, external validation of clinical prediction rules for the identification of extended-spectrum β-lactamase-producing Enterobacterales, University Hospital Basel, Switzerland, January 2010 to December 2016.

Authors:  Isabelle Vock; Lisandra Aguilar-Bultet; Adrian Egli; Pranita D Tamma; Sarah Tschudin-Sutter
Journal:  Euro Surveill       Date:  2020-07

10.  Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections.

Authors:  Alvaro J Martínez-Valencia; Brian J Gómez Martínez; Anita M Montañez Ayala; Katherin García; Ricardo Sánchez Pedraza; Leydy P Jiménez Cetina; Julio C Gómez Rincón; Sonia I Cuervo Maldonado
Journal:  BMC Infect Dis       Date:  2020-07-31       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.